4 hours ago
1
Veronique D
- Takeda Pharmaceutical (NYSE:TAK) said that data from two phase 3 trials on oveporexton for narcolepsy type 1 met all of its primary and secondary endpoints.
- The stock is up ~3% in pre-market trading Monday.
- Oveporexton, a potential first-in-class investigational oral orexin
English (US) ·